Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B"

被引：0
|
作者：
Papatheodoridis, George
Sypsa, Vana
Lampertico, Pietro
机构：
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 74卷 / 01期
关键词：
D O I：
10.1016/j.jhep.2020.09.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：246 / 247
页数：3
相关论文
共 50 条
  • [21] Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
    Papatheodoridis, George V.
    Sypsa, Vana
    Dalekos, George
    Yurdaydin, Cihan
    van Boemmel, Florian
    Buti, Maria
    Goulis, John
    Calleja, Jose Luis
    Chi, Heng
    Manolakopoulos, Spilios
    Loglio, Alessandro
    Siakavellas, Spyros
    Gatselis, Nikolaos
    Keskin, Onur
    Lehretz, Maria
    Savvidou, Savvoula
    de la Revilla, Juan
    Hansen, Bettina E.
    Kourikou, Anastasia
    Vlachogiannakos, Ioannis
    Galanis, Kostantinos
    Idilman, Ramazan
    Colombo, Massimo
    Esteban, Rafael
    Janssen, Harry L. A.
    Berg, Thomas
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2018, 68 (06) : 1129 - 1136
  • [22] Comparison of the long-term efficacy between tenofovir and entecavir in chronic hepatitis B patients
    Liu, Kecheng
    Peng, Peng
    Cai, Fuqing
    Huang, Jiean
    GUT, 2021, 70 (08) : 1599 - 1600
  • [23] Flares during long-term entecavir therapy in chronic hepatitis B
    Chi, Heng
    Arends, Pauline
    Reijnders, Jurrien G. P.
    Carey, Ivana
    Brown, Ashley
    Fasano, Massimo
    Mutimer, David
    Deterding, Katja
    Oo, Ye H.
    Petersen, Jorg
    van Bommel, Florian
    de Knegt, Robert J.
    Santantonio, Teresa A.
    Berg, Thomas
    Welzel, Tania M.
    Wedemeyer, Heiner
    Buti, Maria
    Pradat, Pierre
    Zoulim, Fabien
    Hansen, Bettina E.
    Janssen, Harry L. A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (11) : 1882 - 1887
  • [24] Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy
    Papatheodoridis, George V.
    Dalekos, George N.
    Yurdaydin, Cihan
    van Boemmel, Florian
    Buti, Maria
    Sypsa, Vana
    Goulis, John
    Calleja, Jose L.
    Chi, Heng
    Manolakopoulos, Spilios
    Loglio, Alessandro
    Gatselis, Nikolaos
    Keskin, Onur
    Lehretz, Maria
    Savvidou, Savvoula
    de la Revilla, Juan
    Hansen, Bettina E.
    Vlachogiannakos, Jiannis
    Galanis, Kostas
    Idilman, Ramazan
    Colombo, Massimo
    Esteban, Rafael
    Janssen, Harry L.
    Berg, Thomas
    Lampertico, Pietro
    HEPATOLOGY, 2016, 64 : 35A - 36A
  • [25] RISK ASSESSMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS WITH LONG-TERM ANTIVIRAL THERAPY
    Chung, K. S.
    Lee, H. W.
    Kim, D. Y.
    Kim, B. K.
    Kim, S. U.
    Park, J. Y.
    Han, K. -H.
    Ahn, S. H.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S517 - S517
  • [26] Risk assessment of hepatocellular carcinoma in chronic hepatitis B patients with long-term antiviral therapy
    Chung, Kyu Sik
    Kim, Do Young
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ku, Hye Jin
    Han, Kwang-Hyub
    Ahn, Sang Hoon
    HEPATOLOGY, 2015, 62 : 385A - 385A
  • [27] Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review
    Tseng, Cheng-Hao
    Tseng, Chao-Ming
    Wu, Jia-Ling
    Hsu, Yao-Chun
    El-Serag, Hashem B.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (10) : 1684 - 1693
  • [28] The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients
    Papatheodoridis, George V.
    Yurdaydin, Cihan
    Dalekos, George N.
    Buti, Maria
    Chi, Heng
    van Boemmel, Florian
    Calleja, Jose L.
    Sypsa, Vana
    Goulis, Ioannis
    Manolakopoulos, Spilios
    Loglio, Alessandro
    Siakavellas, Spyros I.
    Keskin, Onur
    Gatselis, Nikolaos
    Hansen, Bettina E.
    Lehretz, Maria
    de la Revilla, Juan
    Savvidou, Savvoula
    Kourikou, Anastasia
    Vlachogiannakos, Jiannis
    Idilman, Ramazan
    Galanis, Kostas
    Berg, Thomas
    Colombo, Massimo
    Esteban, Rafael
    Janssen, Harry L.
    Lampertico, Pietro
    HEPATOLOGY, 2016, 64 : 923A - 923A
  • [29] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Lee, Hye Won
    Cho, Young Youn
    Lee, Hyein
    Lee, Jae Seung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Beom Kyung
    Park, Soo Young
    HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1083 - 1092
  • [30] Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Chang, Jin Won
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Seo, Yeon Seok
    Lee, Han Ah
    Kim, Mi Na
    Lee, Yu Rim
    Hwang, Seong Gyu
    Rim, Kyu Sung
    Um, Soon Ho
    Tak, Won Young
    Kweon, Young Oh
    Park, Soo Young
    Kim, Seung Up
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 95 - 104
12345